A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

Sponsor
Bristol Myers Squibb

Protocol Number
Bristol Myers Squibb CA017-003

To Learn More Call
201-510-0910